ClinicalTrials.gg
CompletedNCT05279807MasolinoUpdated Oct 21, 2024Results posted

Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy

A Phase 4 interventional study of Zofenopril and Amlodipine in Hypertension, sponsored by Menarini International Operations Luxembourg SA. Completed at 1 site in Hungary. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-21.

Sponsored by Menarini International Operations Luxembourg SA (part of Menarini Group) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2021, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
277
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
72nd of 186
277 · median 180
Started
2021
with 3 others
Phase 4
80 of 187
2 open now
Registered
175th of 187
by date

Among the 187 studies testing amlodipine in Hypertension, this one is the 72nd largest by enrollment of the 186 interventional ones that give a count, is one of 4 that started in 2021, is one of 80 in phase 4, and was the 175th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Zofenopril 30 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment in patients with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks.

Read the detailed description

Approximately 290 patients are planned to be screened to ensure at least 216 patients complete the run-in period and start with the assessment period.

Patients with Grade 1-2 hypertensive patients (blood pressure [BP] ranging from ≥140/90 mmHg to ≤179/109 mmHg) on treatment with any angiotensin converting enzyme inhibitors (ACE-i) including Zofenopril (ZOF)30 mg or with calcium channel blockers (CCBs) including Amlodipine (AML)5 mg will be screened for eligibility (Visit 1).

Allowed CCBs: Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine. Patients treated with other dosages of ZOF (other than 30 mg) are not allowed to be screened. After screening, on the same day, eligible patients, will enter into a 4-week run-in period, during which patients on other ACE-i will be assigned to monotherapy with ZOF 30 mg while patients on CCBs will be assigned to monotherapy with AML 5 mg for 4 weeks. Patients with on-going treatment zofenopril 30 mg and amlodipine 5mg will continue on the same treatment for 4 weeks.

After the run-in period (4 weeks ± 2 days), BP will be further assessed (Visit 2), if BP levels are over the defined controlled target goal, sitting Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) >130/80 mmHg, treatment is well tolerated and adherence to the treatments ranges from 80% to 120%, patients will enter the assessment period, where they will be assigned to the extemporaneous combination of ZOF 30 mg and AML 5 mg. At Visit 2 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study.

If patients, at Visit 2, after the run-in period, have a controlled BP (sitting SBP/DBP≤130/80 mmHg) or do not tolerate the treatment or have an adherence range below 80% or superior to 120%, they will be withdrawn from the study.

The patients will be assessed for further 8 weeks (assessment period). After 4 weeks ± 2 days from Visit 2,during the assessment period patients receiving the extemporaneous combination of ZOF 30 mg and AML 5 mg, will be further evaluated (Visit 3): controlled patients (sitting SBP/DBP ≤130/80 mmHg) will continue the same extemporaneous combination for additional 4 weeks ± 2 days, while uncontrolled patients (sitting SBP/DBP >130/80 mmHg) will be up-titrated from ZOF/AML 30/5 mg to ZOF/AML 30/10 mg for further 4 weeks ± 2 days. At Visit 3 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study. If patients at Visit 3, do not tolerate the extemporaneous combination treatment or they have an adherence range below 80% or superior to 120%, they will be withdrawn from the study.

At the end of the assessment period (8 weeks ± 4 days) at Visit 4, the anti-hypertensive effect of the extemporaneous combination (ZOF/AML 30/5 mg and ZOF/AML 30/10 mg) will be evaluated.

Efforts will be made to achieve 1:1 ratio in the enrolment of patients receiving any ACE-i or allowed CCBs (refer to section Subject Study Phases Duration for allowed CCBs). At Visit 2, a minimum of 45% of uncontrolled patients receiving treatment with ZOF 30 mg or AML 5 mg are required to enter the assessment period, in order to maintain a balance between the 2 treatments during the assessment period.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • Combination Therapy
  • Zofenopril
  • Nebivolol
  • Fixed Dose Combination
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female Grade 1-2 hypertensive patients: with mean sitting SBP ≥140 mmHg and ≤179 mmHg and/or mean sitting DBP ≥ 90 mmHg and ≤109 mmHg at Screening, with ≥18 and ≤65 years of age, on monotherapy either with ZOF 30 mg or AML 5mg or any other ACE-I or CCBs (Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine) for at least 1 month before Visit 1 (Screening).
  2. Patients who are able to understand and give written at Screening
  3. Patients who are available for the entire trial period and willing to adhere to the protocol requirements
  4. Ability to take oral medication and willing to adhere to the drug regimen
  5. Female patients are eligible to participate if not pregnant, or not breastfeeding and must refrain from donating or storing eggs. For females of : use of highly effective (e.g., method of birth control throughout the study period and for 4 weeks after study completion defined as a method which results in a failure rate of less than 1% per year) such as:

    • Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
    • Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner (performed at least 2 months before screening) (if the partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success)
  6. A male patient must agree to use contraception during the whole study period and for at least 1 week after the last dose of study treatment and refrain from donating sperms during this period

Exclusion criteria

Exclusion Criteria:

  1. Known , presence of not recommended/contraindicated concomitant therapy allergies, or significant history of to zofenopril, amlodipine, other ACE-inhibitors or dihydropyridines, or any related products including of the formulations as outlined in the Investigator's Brochure (IB), or summary of product characteristics (SmPCs) or local package inserts for AML and ZOF
  2. Patients with serious disorders (in the opinion of the Investigator) which may limit the ability to evaluate the efficacy or safety of the tested medications, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine/ or metabolic, haematological, or oncological, neurological, and psychiatric diseases. The same applies for and/or neutropenic patients
  3. Patients having a history of the following within the last 6 months: myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, bypass surgery, valve replacement (transcatheter aortic valve implantation, mitral-clip),cerebrovascular accident (stroke, heart failure, hypertensive encephalopathy, cerebrovascular accident (stroke), or . Patients with who have undergone other surgery that in the in the opinion of the Investigator may limit the ability to evaluate the efficacy or safety of the tested medications.
  4. Patients with secondary hypertension of any aetiology such as renal diseases, pheochromocytoma, Cushing's syndrome hyperaldosteronism, renovascular disease, thyroid disorders
  5. Patients with severe heart failure ( classification III-IV), a narrowing of the aortic or bicuspid valve, an obstruction of cardiac outflow (obstructive, hypertrophic cardiomyopathy) or symptomatic coronary disease
  6. Patients with clinical evidence of renal disease as per the Investigator's judgement (including renovascular occlusive disease, nephrectomy and/or renal transplant, bilateral renal artery stenosis or unilateral renal artery stenosis in a solitary kidney, or severe renal impairment)
  7. Patients with history of angioneurotic oedema
  8. Patients with hepatic impairment
  9. Patients with sick sinus syndrome, including sino-atrial block
  10. Patients with second- or third-degree heart block (without a pacemaker)
  11. Participation in any other interventional drug trial or exposure to other agents within 30 days before Screening (Visit 1)
  12. Inability to cooperate or any condition that, in the opinion of the Investigator, could increase the patient's risk of participating in the study or confound the outcome of the study
  13. Patients with conditions that, in the opinion of the Investigator, would prevent a careful adherence to the protocol
  14. Patients with severe hypotension
  15. Patients who suffer from shock (including cardiogenic shock)
  16. Patients treated with Amlodipine 10 mg and Zofenopril (other than 30 mg)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
277 participants (actual)

Study arms

  • Active comparator
    Zofenopril 30 mg

    Single dose Phase (4 weeks): patients will be treated with Zofenopril 30 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.

    Drug: Zofenopril · Drug: Amlodipine

  • Active comparator
    Amlodipine 5/10 mg

    Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.

    Drug: Zofenopril · Drug: Amlodipine

Interventions

  • Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.

  • Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)

    To assess the antihypertensive efficacy of the extemporaneous combination of Zofenopril (ZOF) 30 mg in combination with Amlodipine (AML) 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks during run-in period.

    Time frame: From Visit 2 (week 0) to Visit 4 (week 8) for a total of 8 weeks

07

Results

Posted Oct 21, 2024

Participant flow

Participant flow — Overall Study
MilestoneZofenopril 30mgAmlodipine 5/10 mg
Started144133
Completed142132
Not completed21
Withdrew: Withdrawal by subject10
Withdrew: Adverse event01
Withdrew: Laboratory abnormal results10

Outcome measures

PrimaryChange in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)

To assess the antihypertensive efficacy of the extemporaneous combination of Zofenopril (ZOF) 30 mg in combination with Amlodipine (AML) 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks during run-in period.

Time frame:
From Visit 2 (week 0) to Visit 4 (week 8) for a total of 8 weeks
Reported as:
Mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)
mmHgCombination Therapy Phase Zofenopril 30mg/Amlodipine 5 or 10 mg
Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8)-13.5 ± 8.31
Statistical analysis
  • Combination Therapy Phase Zofenopril 30mg/Amlodipine 5 or 10 mg · Paired Samples T-Test · p = < 0.001 · Mean difference pre vs post treatment: -13.5 · 95% CI -14.5 to -12.5

Adverse events

Collected over From Informed Consent signature at screening visit (Visit 1) occurring 4 week previous than Baseline assessment (Week 0 - Visit 2) to last visit at Week 8 (Visit 4) for an average of 12 weeks. Furthermore patients having any ongoing Adverse Event/Serious Adverse Event at the end of the treatment (Week 8 - Visit 4), will be followed for further 2 weeks via a phone call to check about the status of the Adverse Events/Serious Adverse Events, extending the time frame to a total of 14 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zofenopril 30mg MONOTHERAPY PERIOD0/143 (0%)0/143 (0%)8/143 (5.6%)
Amlodipine 5 mg MONOTHERAPY PERIOD0/133 (0%)0/133 (0%)11/133 (8.3%)
Zofenopril 30mg/Amlodipine 5mg COMBINATION THERAPY PERIOD0/149 (0%)0/149 (0%)10/149 (6.7%)
Zofenopril 30mg/Amlodipine 10mg COMBINATION THERAPY PERIOD0/122 (0%)1/122 (0.8%)20/122 (16.4%)
Most frequent serious events
Most frequent serious events
EventZofenopril 30mg MONOTHERAPY PERIODAmlodipine 5 mg MONOTHERAPY PERIODZofenopril 30mg/Amlodipine 5mg COMBINATION THERAPY PERIODZofenopril 30mg/Amlodipine 10mg COMBINATION THERAPY PERIOD
Oesophageal food impactionGastrointestinal disorders0/1430/1330/1491/122
Most frequent other events
Most frequent other events
EventZofenopril 30mg MONOTHERAPY PERIODAmlodipine 5 mg MONOTHERAPY PERIODZofenopril 30mg/Amlodipine 5mg COMBINATION THERAPY PERIODZofenopril 30mg/Amlodipine 10mg COMBINATION THERAPY PERIOD
Respiratory tract infection viralInfections and infestations1/1431/1336/1492/122
COVID-19Infections and infestations1/1434/1330/1494/122
HeadacheNervous system disorders3/1432/1331/1494/122
Back painMusculoskeletal and connective tissue disorders0/1430/1331/1494/122
HyperuricemiaMetabolism and nutrition disorders0/1430/1331/1492/122
GastritisGastrointestinal disorders0/1430/1330/1492/122
NauseaGastrointestinal disorders0/1430/1330/1492/122
Dry MouthGastrointestinal disorders0/1432/1330/1490/122
AstheniaGeneral disorders1/1432/1330/1490/122
DizzinessNervous system disorders2/1430/1331/1490/122

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zofenopril 30mgAmlodipine 5/10 mgTotal
Mean51.1 ± 9.9654.1 ± 9.0352.3 ± 9.83
Sex: Female, Male
Sex: Female, Male(Participants)Zofenopril 30mgAmlodipine 5/10 mgTotal
Female7783160
Male6750117
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zofenopril 30mgAmlodipine 5/10 mgTotal
Hispanic or Latino000
Not Hispanic or Latino144133277
Unknown or Not Reported000
08

Study locations

1 site
  • Investigational site
    Debrecen, 4025, Hungary
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Apr 2022, 6 months.

Results were first posted in Oct 2024, 2 years 5 months after primary completion.

Of 35 industry-sponsored phase 4 interventional studies under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 6 months is below that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Mar 15, 2022
StartActual
Oct 15, 2021
Primary completionActual
Apr 28, 2022
CompletionActual
Apr 28, 2022
Results first posted
Oct 21, 2024
Last update
Oct 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05279807
Responsible party
Sponsor
First posted
Mar 15, 2022
Start date
Oct 15, 2021
Primary completion
Apr 28, 2022
Completion
Apr 28, 2022
Results posted
Oct 21, 2024
Last update
Oct 21, 2024

Study contacts

Massimo Volpe, Professor
principal investigator · University "Sapienza" Rome

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zofenopril · Amlodipine

Start the discussion